glomerular filtration rate

Overview

Glomerular filtration rate (GFR) quantifies kidney function as the volume of plasma cleared by the renal glomeruli per unit time, conventionally expressed in mL/min/1.73 m² of body surface area. Direct measurement requires clearance of an exogenous marker such as inulin or iohexol, so routine practice relies on estimated GFR (eGFR) from serum creatinine, cystatin C or both, using equations such as CKD-EPI, MDRD, or Cockcroft-Gault for creatinine clearance. Each estimate inherits the weaknesses of its marker: creatinine production varies with muscle mass, so eGFR is misleading in the very muscular, the frail and the malnourished, which is why cystatin C is used to confirm a discrepant result. GFR categories define the staging of chronic kidney disease and chronic renal insufficiency; acute kidney injury is diagnosed and staged instead by changes in serum creatinine and urine output, since a rate estimated from a marker that has not yet reached steady state is not meaningful when function is changing quickly.

Physiologically, GFR reflects net filtration pressure across the glomerular capillary wall and the number of functioning nephrons. It falls as nephrons are lost to sclerosis, interstitial fibrosis or hemodynamic injury, processes in which mediators such as transforming growth factor-β1 have established roles. Surviving nephrons compensate by hyperfiltration, which is why a normal GFR can coexist with substantial nephron loss and why serum creatinine rises only after much of the reserve is gone. Estimates are therefore insensitive to early injury and are interpreted alongside blood urea nitrogen, cystatin C and urinary albumin, the last detecting glomerular damage while filtration is still preserved.

GFR is central to drug handling: renally cleared agents require dose adjustment or exclusion below defined thresholds, which is why eGFR governs eligibility and cumulative dosing for nephrotoxic chemotherapy such as cisplatin, monitoring of antiretroviral therapy and immunosuppressive regimens, and safety assessment in diabetic kidney disease. It is also the principal efficacy endpoint in nephroprotection trials, including those of sodium-glucose cotransporter-2 (SGLT2) inhibitors, where the rate of decline over time rather than any single value defines benefit — and where an early dip in eGFR can mark a haemodynamic change that precedes long-term preservation rather than injury.

Recent Publications Summary (latest 30 papers)

Recent publications that included glomerular filtration rate as a study target focused primarily on renal function assessment in oncology and treatment-response modeling. In head and neck cancer patients receiving concurrent chemoradiotherapy, individualized glomerular filtration rate (eGFR) was examined in relation to cumulative cisplatin dose, reflecting the clinical need to balance kidney function with the goal of reaching the commonly cited cumulative cisplatin threshold of at least 200 mg/m2 42373265Jun. A separate methodological study evaluated how acute changes in eGFR may inform the long-term effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors, using principal stratification and a normal copula framework to address bias that can arise when treatment-induced biomarker changes are analyzed naively 42054403Apr.

Across these papers, eGFR was used as a clinically meaningful biomarker rather than a mechanistic target, with emphasis on how renal function influences therapeutic decision-making and interpretation of treatment effects. The cisplatin study specifically framed eGFR as essential for assessing renal reserve during chemoradiotherapy, while the SGLT2 inhibitor analysis treated acute eGFR change as a prognostic biomarker whose relationship to long-term endpoints requires careful causal modeling 42373265Jun42054403Apr.

No recent publication in this set reported direct experimental modulation of glomerular filtration rate itself. Instead, the literature positioned eGFR as a practical clinical metric for renal safety, dose feasibility, and biomarker-based outcome modeling in treatment settings involving cisplatin and SGLT2 inhibitors 42373265Jun42054403Apr.

What Changes, What Holds

1. eGFR is being used as a practical safety and dosing biomarker, not as a new biological target
REINFORCES The new papers keep glomerular filtration rate in the same clinical lane described in the baseline: a renal-function readout that guides cisplatin feasibility and interpretation of treatment effects. What they add is emphasis, not a new role, showing that individualized eGFR remains central to balancing kidney reserve against oncologic dosing goals and to modeling longer-term renal consequences of therapy 42373265Jun42054403Apr.

2. These studies sharpen the biomarker framing without changing the underlying account
REINFORCES Acute eGFR change is treated as a prognostic and decision-making marker, which fits the baseline description of GFR as a clinically meaningful index used alongside other renal measures. The methodological caution about causal interpretation strengthens, rather than challenges, the established view that eGFR is informative but not mechanistically explanatory on its own 42373265Jun42054403Apr.

3. No new biological role for GFR is established here
REINFORCES The recent work does not overturn or extend the baseline into a different function for glomerular filtration rate; it simply reuses the metric in oncology and treatment-response settings. That leaves the established account intact: GFR remains a clinical measure of renal function, with these papers adding no direct experimental modulation or novel physiology to incorporate 42373265Jun42054403Apr.

Overview update candidates: none.